Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in PCD pharma franchise in Hyderabad

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharmaceutical manufacturing company in Mumbai

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in diabetic care pharma franchise in Pune

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma suppliers in Delhi

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma export companies in Kolkata
Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /dapagliflozin-10mg-metformin-tablets-tablet

Dapoflit M Tablet

Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 500mg Tablets

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹267/-

Dapoflit M Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antidiabetic agent. This formulation is used in the management of Type 2 Diabetes Mellitus by improving glycemic control. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion, while Metformin decreases hepatic glucose production and enhances insulin sensitivity. Together, they help in maintaining blood sugar levels and support cardiovascular and renal health in diabetic patients.

Read More

About the Product

Dapoflit M Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antidiabetic agent. This formulation is used in the management of Type 2 Diabetes Mellitus by improving glycemic control. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion, while Metformin decreases hepatic glucose production and enhances insulin sensitivity. Together, they help in maintaining blood sugar levels and support cardiovascular and renal health in diabetic patients.

Common side effects may include urinary tract infections, genital infections, nausea, diarrhea, abdominal discomfort, and increased urination. Rarely, hypoglycemia may occur, especially when combined with other antidiabetic drugs.

Indicated for patients with Type 2 Diabetes Mellitus when diet, exercise, and Metformin monotherapy do not provide adequate glycemic control. Also suitable as part of combination therapy for better blood sugar management.

Not recommended for patients with Type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with renal impairment. Adequate hydration should be maintained to reduce the risk of dehydration.

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation